OpenClaim

Revumenib Side Effects

The most commonly reported side effects of revumenib include off label use, platelet count decreased, and nausea, based on 525 FDA adverse event reports from 2024 to 2025. 4.6% of reports found the drug to be ineffective.

#1 Reported: Off Label UseAll side effects ↓Top Co-Medication: VenetoclaxDrug interactions ↓47% of Reports Are AdultDemographics ↓

Revumenib side effects

Percentages show how often each reaction appears relative to total reports for revumenib.

1
Off Label Use17.9%94
2
Platelet Count Decreased15.6%82
3
Nausea14.5%76
4
Death10.5%55
5
Product Dose Omission Issue10.5%55
6
Vomiting8.2%43
7
Fatigue7.8%41
8
Pyrexia6.9%36
9
Haemoglobin Decreased6.1%32
10
White Blood Cell Count Decreased6.1%32
11
Drug Ineffective4.6%24
12
Diarrhoea4.6%24
13
Neutrophil Count Decreased4.2%22
14
Disease Progression4.2%22
15
Full Blood Count Decreased4.2%22

These are voluntary reports and do not establish that revumenib caused these reactions.

Report severity

55.8%Serious293 reports
28.8%Hospitalizations151 reports
13.1%Fatal69 reports

Seriousness is determined by the reporter, not by OpenClaim.

Revumenib drug interactions

Other drugs that appear in adverse event reports alongside revumenib. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.

Also suspected

1
Venetoclax5.9%31
2
Azacitidine1.0%5
3
Cytarabine0.6%3
4
Diphenhydramine0.2%1
5
Quizartinib-dihydrochloride0.2%1
6
Cedazuridine0.2%1
7
Decitabine0.2%1
8
Asciminib-hydrochloride0.2%1
9
Doxorubicin-hydrochloride0.2%1
10
Dexamethasone0.2%1
11
Cyclophosphamide0.2%1
12
Vincristine-sulfate0.2%1
13
Blinatumomab0.2%1
14
Fludarabine-phosphate0.2%1
15
Inotuzumab-ozogamicin0.2%1

Taken alongside

1
Ondansetron23.2%122
2
Acyclovir19.8%104
3
Venetoclax17.0%89
4
Posaconazole14.9%78
5
Acetaminophen13.5%71
6
Ergocalciferol11.6%61
7
Prochlorperazine9.1%48
8
Allopurinol9.0%47
9
Oxycodone8.6%45
10
Levofloxacin8.4%44
11
Sulfamethoxazole8.2%43
12
Trimethoprim8.2%43
13
Famotidine7.6%40
14
Valacyclovir-hydrochloride7.0%37
15
Azacitidine6.9%36

Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.

Who reports revumenib side effects

41.3% of revumenib adverse event reports involve female patients and 41.3% involve male patients. The largest age group is adult at 47%. These figures reflect who reports side effects, not underlying risk.

Sex

Female41.3%
Male41.3%
Unknown17.3%

Age group

< 23.3%
2–1110.7%
12–175.1%
18–6446.5%
65+34.4%

What is revumenib used for

Conditions and purposes for which patients were taking revumenib when the adverse event was reported.

Acute LeukaemiaAcute Lymphocytic LeukaemiaAcute Megakaryocytic LeukaemiaAcute Monocytic LeukaemiaAcute Myeloid LeukaemiaAcute Myeloid Leukaemia RecurrentAcute Myeloid Leukaemia RefractoryAcute Myelomonocytic LeukaemiaAcute Undifferentiated LeukaemiaAdjuvant TherapyB Precursor Type Acute LeukaemiaKmt2a Gene MutationLeukaemiaLeukaemia RecurrentLymphoma

Showing 15 of 22 indications

Revumenib brand names and reporting trend

Revumenib is sold under the brand name Revuforj.

Brand names

Revuforj13

Quarterly reports (2024–2025)

20242025

An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.

Taking revumenib with another medication?

Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.

Check my medications